Anzeige
Mehr »
Freitag, 17.07.2026 - Börsentäglich über 12.000 News
Von einer Mine zu drei: Wie Goldgroup die Geschichte still und leise verändert hat
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
374 Leser
Artikel bewerten:
(2)

Cell Culture Market worth $58.42 billion by 2031 | MarketsandMarkets

DELRAY BEACH, Fla., June 25, 2026 /PRNewswire/ -- According to MarketsandMarkets, the Cell Culture Market is projected to grow from about USD 33.07 billion in 2026 to USD 58.42 billion by 2031, at a CAGR of 12.1%.

Browse 1000 market data Tables and 57 Figures spread through 765 Pages and in-depth TOC on "Cell Culture Market - Global Forecast to 2031"

Cell Culture Market Size & Forecast:

  • Market Size Available for Years: 2025-2031
  • 2026 Market Size: USD 33.07 billion
  • 2031 Projected Market Size: USD 58.42 billion
  • CAGR (2026-2031): 12.1%

Cell Culture Market Trends & Insights:

  • By product, the consumables segment accounted for the largest share of 73.9% of the market in 2025.
  • By application, the tissue engineering & regenerative medicine segment is expected to register the highest CAGR of 13.9% during the forecast period.
  • North America accounted for the largest share of 39.9% of the market in 2025.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=559

The cell culture market is expected to grow steadily due to increasing biopharmaceutical R&D, rising biologics and biosimilar production, expanding vaccine development, and growing use of cell-based platforms in drug discovery, diagnostics, regenerative medicine, and cell & gene therapy. Cell culture products support cell growth, maintenance, expansion, differentiation, and production across research and manufacturing workflows. Adoption of serum-free and chemically defined media, optimized reagents, culture vessels, single-use bioreactors, filtration systems, cell counters, CO2 incubators, and biosafety cabinets is improving process consistency, scalability, contamination control, and reproducibility. Increasing use of stem cells, organoids, spheroids, 3D culture systems, and patient-derived models is further supporting adoption across pharmaceutical companies, biotechnology firms, CDMOs, hospitals, diagnostic laboratories, academic institutes, CROs, and cell banks.

The market is gradually shifting toward more defined, scalable, and controlled culture systems. While serum-containing and manual workflows remain in use, demand is increasing for serum-free media, chemically defined formulations, closed processing systems, single-use technologies, automated platforms, and high-density bioreactor systems. At the same time, advanced models such as stem cell-derived cells, co-cultures, spheroids, organoids, and organ-on-chip systems are gaining traction for disease modeling, toxicity testing, and translational research. Outsourcing is also increasing as companies rely on CDMOs, CROs, and specialized service providers for process development, cell banking, viral vector production, cell therapy manufacturing, and advanced model development.

By product, the consumables segment accounted for the largest share of the cell culture market in 2025.

By product, the cell culture market is segmented into consumables and equipment. Consumables are further segmented into sera, media, and reagents; vessels; and other consumables & accessories. Equipment is further categorized as bioreactors, storage equipment, and other equipment. The consumables segment dominated the market in 2025 and is expected to grow at a higher rate over the forecast period. The largest share of the segment is attributed to repetitive purchase of media & reagents, and growing R&D activities to develop and manufacture advanced therapies.

Request Sample Pages@https://www.marketsandmarkets.com/requestsampleNew.asp?id=559

By end user, the pharmaceutical & biotechnology companies segment is estimated to register the highest growth in the cell culture market during the forecast period.

Based on end user, the cell culture market is segmented into pharmaceutical & biotechnology companies, hospitals & diagnostic laboratories, academic & research institutes, and other end users. The pharmaceutical & biotechnology companies segment is estimated to register the highest growth rate during the forecast period. The rising demand for advanced therapies, such as regenerative medicine, driven by the increasing prevalence of chronic diseases, is expected to boost growth in the pharmaceutical & biotechnology companies segment in the coming years.

North America accounted for the largest share of the cell culture market in 2025.

The cell culture market is divided into North America, Europe, Asia Pacific (APAC), Latin America (LATAM), the Middle East, and Africa. In 2025, North America held the largest share of the global cell culture market, supported by strong biopharmaceutical and biotechnology R&D activity, advanced biologics manufacturing infrastructure, established cell & gene therapy capabilities, and the presence of leading cell culture product suppliers, CDMOs, CROs, and academic research centers. The US remains the major contributor in the region due to its large base of pharmaceutical companies, government-funded research institutions, clinical trial networks, and advanced therapy developers. High adoption of serum-free media, chemically defined media, single-use bioreactors, culture vessels, filtration systems, cryopreservation products, and automated cell culture platforms further strengthens North America's market leadership.

Inquire Before Buying@https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=559

Top Companies in Cell Culture Market:

The Top Companies in Cell Culture Market include Thermo Fisher Scientific Inc. (US), Danaher (US), Sartorius AG (Germany), Merck KGaA (Germany), Corning Incorporated (US), FUJIFILM Holdings Corporation (Japan), BD (US) Eppendorf SE (Germany), Lonza (Switzerland), Getinge AB (Sweden), Agilent Technologies, Inc. (US), HiMedia Laboratories (India), Miltenyi Biotec (Germany), STEMCELL Technologies (Canada), Solida Biotech GmbH (Germany), Caisson Labs (US), PromoCell GmbH (Germany), InvivoGen (France), PAN-Biotech (Germany), Cellexus (Scotland), Meissner Filtration Products Inc. (US), Adolf Kühner AG (Switzerland), Bio-Techne (US), Advancion Corporation (US), and BioSpherix, Ltd. (US).

Browse Adjacent Markets: Biotechnology Market Research Reports & Consulting

Related Reports:

3D Cell Culture Market - Global Forecast to 2030

Single-use Bioreactors Market - Global Forecast to 2029

Cell Based Assays Market - Global Forecast to 2030

Cell Expansion Market - Global Forecast to 2029

Cell Isolation Market - Global Forecast to 2031

About MarketsandMarkets

MarketsandMarkets has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore, which integrates research and provides ecosystem-wide visibility into revenue shifts.

MarketsandMarkets SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency.

To find out more, visit www.MarketsandMarkets.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/cell-culture-market-worth-58-42-billion-by-2031--marketsandmarkets-302810255.html

© 2026 PR Newswire
Achtung, Korrektur!
Die Börsen laufen heiß. Trotz geopolitischer Krisen und steigender Zinsen klettern viele Indizes weiter Richtung Allzeithoch. Doch unter der Oberfläche zeigen sich erste Risse: Der Abverkauf bei Halbleiter-, KI- und Space-Aktien macht deutlich, wie schnell sich die Stimmung drehen kann.

Besonders gefährlich ist die aktuelle Gemengelage aus schwacher Saisonalität, dünner Liquidität in den Sommermonaten und historisch hohen Bewertungen. Selbst vermeintlich sichere Blue Chips sind inzwischen teuer bewertet und damit anfällig für Korrekturen. Gleichzeitig liefern technische Indikatoren erste Warnsignale. So werden viele Rekordstände nicht mehr bestätigt.

Für Anleger steigen die Risiken spürbar. Wer jetzt nicht genauer hinschaut, läuft Gefahr, auf dem falschen Fuß erwischt zu werden.

In unserem aktuellen Spezialreport zeigen wir fünf Aktien, bei denen die Abwärtsrisiken besonders hoch sind – und wo sich Gewinnmitnahmen oder sogar Short-Strategien anbieten könnten.

Jetzt den kostenlosen Report sichern – bevor die Korrektur Fahrt aufnimmt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.